Results
Animab secures €10M for antibiotic-free animal health solution
Animab, a VUB-VIB-UGent spin-off, has secured €10 million in Series B funding to launch its innovative antibiotic-free solution for piglet health, tackling antimicrobial resistance.
Read more
Calling experts for Horizon Europe/Digital Europe and IPCC-workshops
We are looking for experts for two distinct initiatives within the realm of research and innovation. These calls present a unique opportunity to bolster the Brussels R&I ecosystem at both European and international levels. 1.
Read more
Swave Photonics raises €6M for holographic display technology
Swave Photonics, a spin-off from imec and VUB, has raised an additional €6 million in Series A funding. This follow-on investment will accelerate the development of Swave's innovative holographic display technology for Spatial + AI Computing.
Read more
Unified governance for data and AI
In a world awash with data, making sense of it and keeping it reliable can feel like navigating a stormy sea. From academic research to “unicorn” status, VUB spin-off Collibra redefined how organisations can trust, understand and use their data to create value.
Read more
How VUB spin-offs are reshaping fertility care
From non-invasive embryo selection to hormone-free IVF, VUB innovations are giving fertility care a human-centred upgrade — improving outcomes, access, and safety for people around the world.
Read more
Empowering amputees with a smart bionic foot
What if a prosthetic foot could move as naturally as a biological one? VUB spin-off Axiles Bionics is redefining mobility for lower limb amputees.
Read more
Bringing nature-based resilience to cities
With cities under increasing pressure from floods and heatwaves, BitaGreen transforms urban planning with nature-based solutions that not only protect against climate risks but also improve quality of life.
Read more
Precirix Receives FDA Green Light for Novel Cancer Therapy
VUB spin-off Precirix announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for CAM-FAP-Ac-225. This significant achievement paves the way for Precirix to begin a Phase 1 clinical trial for patients battling FAP-positive tumors.
Read more
SALVUS
The ERIS team proudly announces that the SALVUS consortium has received an EU grant. Prof. Rosamunde Van Brakel, from the Law, Science, Technology and Society Research Group of VUB, will coordinate this project for VUB.
Read more
GULLIVER BIOMED
Read more